Advarra Acquires YourEncore
Advarra has announced the acquisition of YourEncore.
“We’re excited that YourEncore is becoming part of Advarra,” said Gadi Saarony, CEO of Advarra. Together, they will aim to progress a shared vision of accelerating the drug development lifecycle and the delivery of therapies to patients.
Advarra’s consulting services currently assist biopharmaceutical companies, device manufacturers, academic medical centers, health systems, and institutions in nearly 60 countries. “The addition of YourEncore is a huge step forward for Advarra’s consulting services business, building on and broadening our existing team and solutions across the clinical research spectrum,” said Scott Uebele, President and Chief Research Services Officer of Advarra.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
